Target intelligence / Profile preview

White matter

Molecular classification
Other
01

Overview

White matter is a major component of the central nervous system consisting primarily of myelinated axons that facilitate communication between different brain regions (StatPearls, 2022). It is distinguished from grey matter by its high lipid content, which forms the myelin sheath produced by oligodendrocytes to ensure rapid electrical signal transmission (NIH, 2023). Functionally, white matter serves as the structural connectivity network of the brain, supporting cognitive processes and motor coordination by linking cortical and subcortical structures (Filley & Fields, 2016). Pathological degradation of white matter is a hallmark of several neurological disorders, most notably multiple sclerosis, where autoimmune attacks lead to demyelination and axonal loss (PubMed, 2021). Other conditions involving white matter include leukodystrophies, which are genetic disorders affecting myelin metabolism, and vascular dementia resulting from small vessel disease (StatPearls, 2022). While white matter is a tissue type rather than a single molecular target, it is the focus of therapeutic interventions aimed at neuroprotection and remyelination. Drugs such as S1P receptor modulators are used to prevent inflammatory damage to white matter tracts in relapsing-remitting diseases (Nature Reviews Drug Discovery, 2018).

Other names
Substantia albaWhite substanceMyelinated axonsCNS tracts
02

Mechanism of action

White matter is an anatomical tissue rather than a molecular target; drugs associated with white matter typically target specific receptors (e.g., S1P receptors) or immune cells to prevent demyelination or promote repair (StatPearls, 2022).

03

Biological functions

Neural signalingAxonal conductionInter-hemispheric communicationMetabolic supportOther
04

Disease associations

Neurodegenerative diseaseInfectionOther
05

Safety considerations

Progressive multifocal leukoencephalopathy (PML)NeurotoxicityLeukoencephalopathyBlood-brain barrier disruption
06

Interacting drugs

Fingolimod

4 more in the full profile.

07

Biomarkers

Fractional anisotropy (MRI)Mean diffusivity (MRI)Neurofilament light chain (NfL)Myelin basic protein (MBP)T2-weighted lesion volume

Beyond the preview

Go deeper on White matter.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on White matter.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call